References
- Engstrom K, Wojdacz TK, Marabita F, et al. Transcriptomics and methylomics of CD4-positive T cells in arsenic-exposed women. Arch Toxicol. 2017;91(5):2067–2078.
- Snell C, Krypuy M, Wong EM, et al. BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res. 2008;10(1):R12.
- Nuovo GJ, Plaia TW, Belinsky SA, et al. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci U S A. 1999;96(22):12754–12759.
- Mittag F, Kuester D, Vieth M, et al. DAPK promotor methylation is an early event in colorectal carcinogenesis. Cancer Lett. 2006;240(1):69–75.
- Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998;95(20):11891–11896.
- Nian J, Sun X, Ming S, et al. Diagnostic accuracy of methylated SEPT9 for blood-based colorectal cancer detection: a systematic review and meta-analysis. Clin Transl Gastroenterol. 2017;8(1):e216.
- Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287–1297.
- Shen L. Personalized medicine: four perspectives of tailored medicine AU - Ruberg, Stephen J. Stat Biopharm Res. 2015;7(3):214–229.
- Hao X, Luo H, Krawczyk M, et al. DNA methylation markers for diagnosis and prognosis of common cancers. Proc Natl Acad Sci U S A. 2017;114(28):7414–7419.
- Wojdacz TK, Windelov JA, Thestrup BB, et al. Identification and characterization of locus-specific methylation patterns within novel loci undergoing hypermethylation during breast cancer pathogenesis. Breast Cancer Res. 2014;16(1):R17.
- Daugaard I, Hussmann D, Kristensen L, et al. Chronic lymphocytic leukemia patients with heterogeneously or fully methylated LPL promotor display longer time to treatment. Epigenomics. 2018;10(9):1155–1166.
- Daugaard I, Dominguez D, Kjeldsen TE, et al. Identification and validation of candidate epigenetic biomarkers in lung adenocarcinoma. Sci Rep. 2016;6:35807.
- Young GP, Pedersen SK, Mansfield S, et al. A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer. Cancer Med. 2016;5(10):2763–2772.
- Murray DH, Baker RT, Gaur S, et al. Validation of a circulating tumor-derived DNA blood test for detection of methylated BCAT1 and IKZF1 DNA. J Appl Lab Med AACC Publ.2017; DOI: 10.1373/jalm.2017.023135.